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Background and aims: Arginase1 (Arg1), an M2 macrophage marker, plays a critical role in a number of
immunological functions in macrophages, which are the main cell type facilitating atherosclerotic lesion
development. Arg1 uses the substrate L-arginine to create L-ornithine, a precursor molecule required for
collagen formation and vascular smooth muscle cell differentiation. By reducing L-arginine availability,
Arg1 limits the production of nitric oxide (NO), a pro-atherogenic factor in macrophages. In endothelial
cells, conversely, NO is strongly anti-atherogenic. However, until now, the role of Arg1 in atherosclerosis
is largely unknown. The aim of this study is to speciﬁcally investigate the effect of Arg1 deletion in
hematopoietic cells on atherosclerosis susceptibility.
Methods: Ldlr KO mice were transplanted with Arg1ﬂox/ﬂox;Tie2-Cre (Arg1 KO) bone marrow (BM) or
wildtype (WT) BM. After 8 weeks of recovery on chow diet, recipients mice were fed a Western-Type Diet
(WTD) for 10 weeks to induce atherosclerosis.
Results: After 10-week WTD challenge, blood leukocyte counts were decreased by 25% (p < 0.001), and
spleen leukocytes were decreased by 35% (p ¼ 0.05) in Ldlr KO mice transplanted with Arg1 KO BM
compared to mice transplanted with WT BM. The decrease in leukocytes was due to lower B lymphocyte
counts. However, oxLDL-speciﬁc antibodies were increased in plasma of Ldlr KO mice transplanted with
Arg1 KO BM compared toWT BM transplanted controls, whereas oxLDL-speciﬁc IgM was not affected. On
the other hand, peritoneal foam cells in Arg1 KO BM recipients were increased 3-fold (p < 0.001)
compared to WT BM recipients. No change in blood cholesterol was found. Despite changes in leukocyte
counts and macrophage foam cell formation, we did not observe differences in atherosclerotic plaque
size or plaque macrophage content in the aortic root. Surprisingly, there was also no difference in plaque
collagen content, indicating that absence of macrophage Arg1 function does not reduce plaque stability.
Conclusions: Deletion of Arg1 in hematopoietic cells adversely affects blood leukocyte counts and in-
creases foam cell formation. However, no effects on atherosclerosis could be demonstrated, indicating
that hematopoietic Arg1 function is not a decisive factor in atherosclerotic plaque formation.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inhibition of the activity of the enzyme arginase 1 (Arg1) is
considered a promising novel therapeutic strategy for the treat-
ment of cardiovascular disease [1]. In line, arginase inhibition bytics, Leiden Academic Centre
teinweg 55, 2333 CC Leiden,
.
Ireland Ltd. This is an open accessN(omega)-hydroxy-nor-l-arginine (nor-NOHA) improves endothe-
lial function in familial hypercholesterolemia patients and reduces
atherosclerotic lesion development in carotid arteries of apolipo-
protein E (Apoe) knockout mice exposed to low shear stress [2e4].
Arg1 inﬂuences a number of processes implicated in the patho-
genesis of atherosclerosis [5e8]. It is expressed in endothelial cells,
vascular smooth muscle cells (VSMCs) andmacrophages, which are
all important cellular components of the atherosclerotic plaque [1].
Depending on the cell type it is expressed in, Arg1 function is ex-
pected to exert different effects on atherosclerotic plaque
formation.article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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thine from L-arginine [9]. L-arginine, however, is also used as a
substrate by the enzymes inducible- and endothelial nitric oxide
synthase (Inos and Enos) for the production of the endothelial-
protective signalling molecule nitric oxide (NO) [2,10]. By compe-
tition for the common substrate L-arginine, Arg1 can thus indirectly
inhibit the synthesis of NO [11,12]. In line, endothelial Arg1 con-
tributes to endothelial activation and vascular stiffness by reducing
the L-arginine pool, leading to Enos uncoupling and reduced NO
production [10,13]. This results in endothelial activation and
increased recruitment of immune cells to the plaque [10,13].
However, atheroprotective effects have also been described for
Arg1 in macrophages and VSMCs. By producing L-ornithine, Arg1
contributes to the synthesis of L-proline by the enzyme Ornithine
Amino Transferase (OAT), which is a precursor for collagen
biosynthesis. Ornithine can also be metabolised into polyamines,
which leads to increased VSMC differentiation and decreased
inﬂammation [14e16]. In agreement, lentiviral-mediated upregu-
lation of Arg1 in a balloon-injury rabbit model inhibited plaque
inﬂammation and augmented VSMC proliferation. Plaque size was,
however, not affected [8].
In macrophages, Arg1 is found in the alternatively activated M2
cells, a macrophage subtype with an anti-inﬂammatory and wound
healing function [6]. Downregulation of Arg1 expression and in-
hibition of Arg1 activity in Raw264.7 macrophages resulted in
augmented LPS-induced Tnf-a and IL-6 secretion [8]. On the other
hand, Arg1 in macrophages suppresses Th2 dependent inﬂamma-
tion by dampening the production of anti-inﬂammatory cytokines
by CD4þ Tcells and suppressing T-cell proliferation inmice infected
with the trematode Schistosoma mansoni [17]. Differential gene
expression analysis in macrophages of atherosclerosis-susceptible
and -resistant rabbits suggested that high macrophage Arg1
expression was associated with low atherosclerosis susceptibility
[18]. Furthermore, M2 macrophages are found predominantly in
carotid plaques of asymptomatic patients that have more stable
plaques [19], indicating the positive association between macro-
phages of the M2 phenotype and atherosclerotic plaque stabiliza-
tion. However, the functional role of macrophage Arg1 in
atherosclerotic plaque development is currently still unknown.
In this study we speciﬁcally assessed the contribution of he-
matopoietic Arg1 to the development of atherosclerosis by trans-
planting bone marrow from Arg1ﬂox/ﬂox;Tie2Cre mice into
atherosclerosis-susceptible Ldl receptor knockout (Ldlr KO) mice.
2. Materials and methods
2.1. Animals
Ldlr KO mice and WT C57Bl/6 were obtained from the Jackson
Laboratory and expanded at the Faculty of Science, Leiden Univer-
sity. Arg1ﬂox/ﬂox;Tie2Cre (Arg1 KO) mice [20] were bred at the Fac-
ulty of Life Sciences, University of Manchester. All animal studies in
the Netherlands were approved by the regulatory authority of
Leiden University and carried out in compliance with the Dutch
government guidelines. All animal work in the United Kingdom
was performed in accordance with Home Ofﬁce regulations.
2.2. mRNA expression analysis by real time PCR
Thioglycollate-elicited peritoneal macrophages (PMs) from 12-
week old male C57Bl/6 mice was obtained after injection of 1 mL
of 3% thioglycollate solution 5 days prior to the experiment. After
adherence and washing, the macrophages were incubated with/
without 10 mg/mL oxidized low density lipoprotein (oxLDL, pre-
pared as described previously [21]) for 24 h. After that, cells werecollected for total RNA isolation [22]. Subsequently, RevertAid M-
MuLV enzyme (Fermentas, Burlington, Canada) was used to tran-
scribe RNA to cDNA. Quantitative PCR (qPCR, ABI PRISM 7500 sys-
tem, Foster City, CA) was used to access the mRNA expression levels
of genes interested using SYBR Green reagents (Applied Bio-
systems). Rpl27 and 36B4 were used as housekeeping genes.
2.3. Microarray analysis
Twelve-week old female Ldlr KO mice were ﬁrst fed Western-
type Diet (WTD; Special Diet Services) that contains 15% cacao
butter and 0.25% cholesterol for a run-in period of 2 weeks before
bilateral perivascular collar placement in the carotid arteries. Then
the mice were challenged with WTD for another 2 weeks to induce
early atherosclerotic lesion development. The carotid arteries were
isolated directly after the run-in WTD period (baseline group) or 2
weeks after collar-placement (atherosclerotic plaque group) for
microarray analysis as previously described [23].
2.4. Bone marrow transplantation
Bone marrow frommale C57Bl/6 WT controls and Arg1 KO mice
(around 12 weeks old) was prepared for bone marrow trans-
plantation (BMT) to 12 weeks old female Ldlr KO recipient mice. In
brief, lethally irradiated recipients received 5  106 bone marrow
cells via tail vein injection. The mice were allowed to recover for 8
weeks on chow diet (RM3; Special Diet Services), after which they
were fed WTD to induce atherosclerosis. After the 10-week WTD
challenge, the mice were anaesthetized by a lethal dose anesthetic
mixture that contains rompun, ketamine and atropine. Mice were
bled and perfused with PBS, after which organs were isolated. The
hematologic chimerismwas conﬁrmed in genomic DNA of recipient
bonemarrow using the PCRmethod (Supplementary Fig. 1A and B).
2.5. Generation of bone marrow-derived macrophages (BMDMs)
Bone marrow from Ldlr KO recipients transplanted with WT BM
or Arg1 KO BMwas isolated at sacriﬁce for the in vitro experiments.
Bone marrow-derived macrophages were obtained as described
previously [24]. Macrophages were cultured for 24 h with or
without 100 mg/mL acetylated-low density lipoprotein (acLDL). The
preparation of acLDL is described previously [25]. Subsequently the
cells were analysed by an automated veterinary haematology
analyzer (Sysmex Corporation, XT-2000iV, Japan) for foam cell
formation as described previously [26,27]. Brieﬂy, the Sysmex XT-
2000iV analyzer applies a similar principle for cell differential
analysis as patented ﬂuorescent ﬂow cytometric analysis [28]. Laser
side scatter and side ﬂuorescence lights were used for separating
cell clusters. Lipid-rich macrophages (foam cells) are larger and
contain more abundant granules compared to the non-foam cells
[26,27]. Thus in a differential scattergram, the lipid-rich macro-
phage population shifts to a larger scale on the side scatter axis and
side ﬂuorescent light axis, enabling gaiting of a separate, shifted
population of macrophage foam cells.
2.6. Flow cytometry analysis and WBC differential analysis
Blood samples, anti-coagulated with EDTA, as well as single
splenic cell suspensions, were obtained using a 70 mm cell strainer
(734-0003, VWR), were used for FACS analysis. Erythrocyte lysis
buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH ¼ 7.3) was
used to lyse red blood cells in the blood samples and splenocyte
preparations. Consecutively, the cells were analysed on a FACS
Canto II (BD Biosciences, Mountain View, CA) using the relevant
FACS antibodies (all obtained from eBioscience).
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poration, Japan) was used to analyse leukocyte counts in spleen and
blood samples. Furthermore, peritoneal leukocytes collected at
sacriﬁce from the bone marrow transplanted animals were ana-
lysed for quantiﬁcation of macrophage foam cells formation.
2.7. Serum cholesterol level determination
Total and free cholesterol concentrations in serum were deter-
mined using an enzymatic colorimetric method as described pre-
viously [29]. Absorbance was read at 490 nm.
2.8. ELISA assay for anti-oxLDL antibodies
Copper-oxLDL was prepared as previously described [21]. The
mouse immunoglobulin isotyping ELISA kit was obtained from BD
Biosciences (Catalog No. 550487). HRP labelled polyclonal rabbit
anti-Rat immunoglobulins (Ig) were obtained from DAKO (Product
No. P045001). Total Ig and IgM antibodies against oxLDL were
measured by a modiﬁed ELISA. In brief, oxLDL was coated in an
ELISA plate (Corning, NY, 14831) in a concentration of 10 mg/mL
overnight at 4 C in coating buffer (0.42% w/v NaHCO3, 0.53%
Na2CO3, pH of 9.6). After washing with 0.05% tween-20-PBS, wells
were blocked for 30 min in 1% BSA blocking buffer. After washing,
4 mL plasma was added and plates were incubated at room tem-
perature for an hour, thenwashed. For determination of total Ig, the
HRP-labelled rat anti-mouse Ig antibody included in the BD ELISA
kit was added. After incubation for 1 h at room temperature and
subsequent washing, the plate is ready for colour development. For
the IgM determination, after incubation with IgM-speciﬁc rat anti-
mouse antibody for 1 h, wells were incubated with HRP-labelled
rabbit anti-rat Ig for another hour before colour development
following themanufacturer's instruction. Optical density (OD)were
obtained by reading the plate in a plate reader (Biotek, poo-
werWave 340) at 450 nm and 570 nm. Wavelength correction was
performed by subtracting the values obtained at 570 nm from the
values at 450 nm.
2.9. Histological analysis of the aortic root
After 10-week WTD feeding, mice were sacriﬁced. Seven-mm
serial sections of the aortic root were cut using a Leica cryostat. Oil
red-O staining, MoMa2 staining and Masson Trichrome kit were
used for visualization of plaque area, macrophage positive area and
collagen content respectively as described previously [29]. Quan-
tiﬁcation was performed using the Leica image analysis system
(Leica Ltd, Cambridge, UK) [29].
2.10. Statistical analysis
Student's t-test or two-way ANOVAwere used to determine the
statistically signiﬁcant differences (Graphpad Prism software). A
Welch correction was applied to the t-test in the case of unequal
variances in the dataset. The statistical signiﬁcance was set at 0.05.
Results are shown as the mean ± SEM.
3. Results
3.1. Arg1 expression is induced in macrophages by oxLDL loading
and in carotid arteries upon induction of collar-induced
atherosclerosis
The early stages of atherosclerotic lesion development are
characterized by the accumulation of lipid-laden macrophages.
Therefore, ﬁrst the effects of incubation of macrophageswith oxLDLand induction of collar-induced atherosclerosis in the carotid artery
on the expression of Arg1 was determined. In agreement with a
previous study from Gallardo-Soler et al. [30], Arg1 mRNA expres-
sion was increased 4.3-fold in thioglycollate-elicited peritoneal
macrophages after 24 h oxLDL (10 mg/mL) loading (p < 0.001;
Fig.1A) after a qPCR analysis. Oil-red O staining conﬁrmed that after
oxLDL incubation, foam cells were successfully induced (Fig. 1B).
Moreover, microarray analysis showed that Arg1 expression was
signiﬁcantly increased in collar-induced early atherosclerotic le-
sions in the carotid artery of Ldlr KO mice (4.5-fold, p < 0.01;
Fig. 1C).
3.2. Arg1 deletion in bone marrow-derived cells of Ldlr KO mice
increases foam cell accumulation in the peritoneum in absence of
effects on serum total cholesterol levels
To generate a mouse model that speciﬁcally lacks Arg1 in bone
marrow-derived cells, bone marrow (BM) from Arg1ﬂox/ﬂox;Tie2Cre
(Arg1 KO) mice and WT controls was transplanted into Ldlr KO
recipients. In Arg1ﬂox/ﬂox;Tie2Cremice Arg1 has been deleted in cells
of the hematopoietic lineages and in endothelial cells [19,31].
Niese et al. previously showed that Arg1 deﬁciency does not
affect bonemarrow engraftment [32]. In agreement PCR analysis on
genomic DNA isolated from bone marrow after 10 weeks of WTD
feeding conﬁrmed successful disruption of Arg1 functionality in the
bone marrow and peritoneal cells of the Ldlr KO recipient mice
(Supplementary Fig. AeC).
Differential haematology analysis was performed on peritoneal
cells harvested from Ldlr KOmice transplanted with Arg1 KO orWT
bone marrow after 10 weeks of WTD feeding. No difference in total
number of peritoneal leukocytes (data not shown) or the percent-
age of macrophages within the peritoneal leukocyte population
were found between Arg1 KO BM recipients and WT BM recipients
(p > 0.05, Fig. 2A). Interestingly, a 3-fold larger fraction of foam cells
in the peritoneum of Arg1 KO BM recipients was found when
compared to the WT BM recipients (p < 0.001, Fig. 2B). This
increased foam cell formation could not be attributed to increased
serum cholesterol levels, as no difference in serum free cholesterol
(data not shown) or total cholesterol was found (p > 0.05; Fig. 2C).
3.3. Arg1 KO BMDMs show increased foam cell formation and tend
to differentiate to an M2 macrophage phenotype upon acLDL
stimulation
BMDMs from WT and Arg1 KO mice were treated with 100 mg/
mL acLDL for 24 h to gain mechanistic insight into the observed
increased foam cell formation in vivo. AcLDL-induced lipid loading
led to foam cell formation in bothWT BMDMs and Arg1 KO BMDMs
(4.7 ± 0.3% to 10.4 ± 1.1% for WT BMDMs, p < 0.01; and 6.5 ± 0.66%
to 15.1 ± 1.8% for Arg1 KO BMDMs, p < 0.001, respectively; Fig. 2D).
Interestingly, both before and after lipid loading Arg1 KO BMDMs
displayed a 50% increase in foam cell formation compared to WT
BMDMs (p < 0.05, Fig. 2D). The mRNA expression of the genes
related to foam cell formation were also assessed by qPCR analysis
in BMDMs incubated with/without 100 mg/mL acetylated LDL for
24 h. Upon acLDL loading, the expression of Sr-b1, a receptor for
native and modiﬁed lipoproteins, was effectively downregulated in
WT BMDMs (p < 0.05 as compared to non-loaded cells; Fig. 3A),
whereas Arg1 KO BMDMs failed to downregulate Sr-b1 upon acLDL
loading (p > 0.05, Fig. 3A). No differences were observed in Ldlr
expression between the 2 genotypes either with or without acLDL
loading (p > 0.05; Fig. 3B). Foam cell formation is determined by the
balance between cholesterol uptake and synthesis on the one hand
and cholesterol efﬂux on the other hand. Although the expression
of Abca1, the primary cholesterol efﬂux transporter, was increased
Fig. 1. Arg1 expression was induced by oxLDL loading in wild-type (WT) thioglycollate-elicited peritoneal macrophages (PMs) or Western-type diet (WTD) and collar-induced
atherosclerosis in the carotid artery. (A) Thioglycollated-elicited PMs were incubated with/without 10 mg/mL oxLDL for 24 h, and then qPCR was used for analysis of Arg1 gene
expression. (n ¼ 6). (B) Oil-red O staining of PMs after incubation with/without 10 mg/mL oxLDL for 24 h. (C) Ldlr KO mice were challenged with WTD 2 weeks before the collar
placement (baseline). The experimental group was fed WTD for another 2 weeks after collar placement (atherosclerotic plaque). Then the collar-induced atherosclerotic plaques in
carotid arteries of Ldlr KO mice were used for microarray analysis of which the effects on Arg1 expression are shown (n ¼ 6). Results are expressed as mean ± SEM, signiﬁcance was
assessed by Student t-test. **p < 0.01; ***p < 0.001.
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KO, 3.7-fold, p < 0.01; Fig. 3C), no difference in Abca1 expression
was found upon comparison of the Arg1 KO and the WT BMDMs
(p > 0.05, Fig. 3C). Notably, expression of Srebp1 was 2.45-fold
higher in Arg1 KO BMDMs compare to WT BMDMS in response
to acLDL loading, whereas no difference was found under control
non-loaded conditions (Control, p > 0.05; þacLDL, p < 0.05;
Fig. 3D). The difference in Srebp1 expression between acLDL loaded
Arg1 KO and WT macrophages is explained by a failure of the Arg1
KO macrophages to downregulate Srebp-1 in response to acLDL
loading (WT, p < 0.01; Arg1 KO, p > 0.05; Fig. 3D). Furthermore, the
M1 and M2 markers Inos and Fizz-1 were determined in both ge-
notypes of BMDMs before and after acLDL loading. Under control
non-loaded conditions, no differences were found in the expression
of Inos or Fizz-1. However, in response to acLDL loading, Arg1
deﬁciency in BMDMs led to an M2-like phenotype, as evidenced by
signiﬁcantly downregulated Inos expression (67% decrease,
p < 0.05; Fig. 3E) and extremely upregulated Fizz-1 expression (19-
fold, p < 0.001; Fig. 3F), whereas no such changes were observed in
WT BMDMs.
Furthermore, NO production was determined in the culture
medium ofWTand Arg1 KO BMDMs, both under control conditions
and after acLDL lipid loading. Two-way ANOVA showed anincreased NO production in Arg1 KO BMDMs compared to the WT
BMDMs (p¼<0.05, Fig. 3G). NO production was signiﬁcantly
increased (1.6-fold, p < 0.05, Fig. 3G) in Arg1 KO BMDMs, but not in
WT BMDMs in response to acLDL loading, leading to 2.2-fold
(p < 0.01, Fig. 3G) higher NO concentrations in the supernatant of
Arg1 KO BMDMs under these conditions.
3.4. Bone marrow Arg1 deﬁciency affects neither atherosclerotic
plaque size nor plaque composition in Ldlr KO mice
After 10 weeks WTD feeding, the aortic root was sectioned and
stained with oil red-O to analyse atherosclerotic lesion develop-
ment. Despite the observed increase in macrophage foam cell for-
mation upon deletion of Arg1, no difference in plaque size was
found between the two experimental groups (647 ± 29 *103 mm2 for
WT BM recipients vs. 634 ± 26 *103 mm2 for Arg1 KO BM recipients,
Fig. 4A). Macrophages in the plaque were visualized by MOMA-2
staining. No difference in plaque macrophage content as a frac-
tion of total plaque size was observed (0.171 ± 0.011 WT BM vs.
0.169 ± 0.016 Arg1 KO BM, Fig. 4B). Collagen in the plaque was
stained using a Masson Trichrome method and Picosirius Red
staining. A trend towards a reduction in the collagen content of
plaques of Arg1 KO BM recipients was found in Masson Trichrome-
Fig. 2. Increased in vivo peritoneal foam cell formation in Ldlr KO mice transplanted with Arg1 KO BM in absence of effects on serum cholesterol and augmented in vitro foam cell
formation in bone marrow-derived macrophages (BMDM) lacking Arg1. Serum and peritoneal leukocytes were collected at sacriﬁce after 10 weeks of high-fat, high-cholesterol
Western-type diet feeding. (A) Macrophage percentage of total peritoneal leukocytes in BMT recipients (n ¼ 9e14). (B) Foam cell percentage of total peritoneal leukocytes in the
BMT recipients (n ¼ 9e14). (C) Total cholesterol level in BMT recipients (n ¼ 9e14). (D) In vitro, BMDMs fromWT BM or Arg1 KO BM recipients were incubated 24 h in the presence
or absence of 100 mg/mL acLDL. Foam cell percentage was detected using a haematology analyzer (n ¼ 6e10). Results are expressed as mean ± SEM, signiﬁcance was assessed by
Student t-test or 2-way ANOVA. *p < 0.05; **p < 0.01; ***p < 0.001.
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BM, p ¼ 0.06, Fig. 4C). However, analysis of Picosirius Red staining
did not indicate any difference between the groups (0.124 ± 0.013
WT BM vs. 0.105 ± 0.012 Arg1 KO BM, Fig. 4D).
3.5. Transplantation of Arg1 KO bone marrow into Ldlr KO
recipients results in reduced splenocyte and blood leukocyte counts
Flow cytometry was used to assess whether loss of Arg1 func-
tionality in bone marrow-derived cells in the transplanted Ldlr KO
mice affected leukocyte numbers in the circulation or the spleen.
On chow diet, no difference in total blood leukocyte numbers was
detected (p > 0.05, Fig. 5A) between the recipient micewithWT BM
and the mice with Arg1 KO BM. WTD feeding for 10 weeks
increased total leukocyte counts from in blood of Ldlr KO mice
transplanted with WT BM (chow diet: 11410 ± 708 cells/ml; WTD:
15672± 689 cells/ml; p< 0.01; Fig. 5A). Mice transplantedwith Arg1
KO bone marrow, however, failed to show an increase in blood
leukocyte counts uponWTD feeding (chow diet: 12092 ± 906 cells/
ml; WTD: 11573 ± 491 cells/ml; p > 0.05; Fig. 5A). Therefore, it led to
lower total leukocyte counts in the blood of Arg1 KO BM recipients
as compared WT BM recipients after 10 weeks of WTD feeding
(p < 0.001, Fig. 5A). Comparison of the subtypes of WBC, showed
that, in contrast to WT BM recipients in which lymphocytes were
1.6-fold increases (p < 0.001) after 10 weeks WTD feeding,lymphocytes did not increase in Ldlr KO mice transplanted with
Arg1 KO BM (Fig. 5B). No differences were found in neutrophils,
monocytes, and eosinophils (data not shown). Next, ﬂow cyto-
metric analysis was used to determine the effects on the different
cellular subsets in blood at sacriﬁce. No differences were found in
the absolute amounts of CD11bþ cells, CD11bþ/Ly6Chi inﬂamma-
tory, CD11bþ/Ly6Clowþmed patrolling monocytes and CD11bþ/Ly6Gþ
neutrophils, nor the amounts of CD4þ T helper cells, CD25þ/CD4þ
activated T helper cells and CD8þ cytotoxic T-cells (Fig. 5CeH).
Unexpectedly, the decrease in total blood leukocytes appeared to be
driven by a 2-fold decrease in circulating CD19þ B cells (p < 0.01,
Fig. 5I).
At the time of sacriﬁce spleens were taken and weighed. Organ
weight was normalized for total body weight. A small but signiﬁ-
cant 10% decrease in spleen weight was found in Ldlr KO mice
transplanted with Arg1 KO BM (p < 0.05, Fig. 6A), while there were
no differences in total body weight (data not shown). Corre-
spondingly, spleens from the Arg1 KO BM recipients contained 35%
less splenocytes (p ¼ 0.052, Fig. 6B). Next, splenocyte composition
was assessed by ﬂowcytometry. The absolute numbers of leukocyte
subtypes, including CD11bþ cells, CD11bþ/Ly6Chi pro-inﬂammatory
monocytes, CD11bþ/Ly6Clowþmed patrolling cells, CD11bþ/Ly6Gþ
neutrophils, CD19þ B cells and CD8þ Tcells in the spleen of Arg 1 KO
recipients showed a signiﬁcant decrease or a trend towards a
decrease, suggesting that the decrease in splenocyte number was
Fig. 3. Gene expression and nitric oxide production in WT and Arg1 KO BMDMs after incubation with or without 100 mg/mL acLDL for 24 h. Relative mRNA expression of (A) Sr-b1,
(B) Ldlr, (C) Abca1, (D) Srebp1, (E) Inos, and (F) Fizz-1. (Control group, n ¼ 9e12; þacLDL group, n ¼ 3e4). (G) Nitric oxide concentrations in the supernatant of BMDMs incubated with
or without 100 mg/mL acLDL 24 h (Control group, n ¼ 3; þacLDL group, n ¼ 4). Results are expressed as mean ± SEM, signiﬁcance was assessed by Student t-test or 2-way ANOVA.
*p < 0.05; **p < 0.01; ***p < 0.001.
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Fig. 4. Deletion of Arg1 in bone marrow-derived cells does not inﬂuence atherosclerotic lesion development after 10-week WTD feeding. (A) Plaques were stained with oil-red O
and plaque area was quantiﬁed. (p > 0.5; WT BMT, n ¼ 16; Arg1 KO BMT, n ¼ 15). (B) Plaque area stained positively with MOMA-2 antibody was measured and normalized for total
lesion size. (p > 0.5; WT BMT, n ¼ 14; Arg1 KO BMT, n ¼ 16). (C) Plaque collagen was visualized using Masson's Trichrome Staining and plaque collagen content was analysed.
(p ¼ 0.064; WT BMT, n ¼ 15; Arg1 KO BMT, n ¼ 15). (D) Sirius Red staining was performed to examine plaque collagen content further. Collagen content was analysed (p > 0.5; WT
BMT, n ¼ 11; Arg1 KO BMT, n ¼ 12). (E) Representative images of the staining described above. Results are expressed as mean ± SEM, signiﬁcance was assessed by Student t-test.
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Fig. 5. Decreased leukocytes in blood of Ldlr KO mice transplanted with Arg1 KO BM after 10 weeks of feeding a high-fat, high-cholesterol Western-type diet (WTD).
After BMT, recipient mice were fed chow diet for 8 weeks (shown as “chow diet” in ﬁgures) before the switch to WTD for an additional 10 weeks (shown as “WTD” in ﬁgures) to
induce atherosclerosis development. Circulating leukocytes (A) and lymphocytes (B) on chow diet at 8 weeks after transplantation and after 10 weeks on WTD at 18 weeks after
transplantation. (n ¼ 15e19). (B) Circulating lymphocytes at 8 weeks after transplantation on chow diet and 10 weeks on WTD. (n ¼ 15e19). (CeI) Circulating leukocytes were
analysed by ﬂow cytometry for expression of several immune cell markers. (n ¼ 5). (F) Total CD19þ cells in circulation (n ¼ 5). (J) Representative ﬂow cytometry plots. Results are
expressed as mean ± SEM, signiﬁcance was assessed by Student t-test or 2-way ANOVA. *p < 0.05; **p < 0.01; ***p < 0.001.
B. Ren et al. / Atherosclerosis 256 (2017) 35e4642not attributable to one speciﬁc cell type (p < 0.05, Fig. 6C and D).
However, fractional analysis showed a 23% increase in CD4þ and
CD25þ/CD4þ Tcells in the spleen of Ldlr KOmice that received Arg1
KO BM compared to the recipients that received WT BM (*p < 0.05;
$p < 0.05, respectively. Fig. 6E).3.6. Arg1 deﬁciency in the bone marrow of Ldlr KO mice induces
circulating oxLDL-speciﬁc antibody levels
The total level of ox-LDL speciﬁc immunoglobulins (Ig) and its
isotype IgM were determined in plasma of the Ldlr KO mice
Fig. 6. Decreased spleen weight in Ldlr KO mice transplanted with Arg1 KO BM. Spleens were isolated at 10 weeks after feeding a high-fat, high-cholesterol Western-type diet. (A) A
reduction in relative spleen weight was measured in the Arg1 KO BM recipients. The readout was corrected for the total body weight of mice (*p < 0.05; WT BMT, n ¼ 11; Arg1 KO
BMT, n ¼ 14). (B) Reduction in total amount of splenocytes in the Arg1 KO BM recipients (p ¼ 0.05; WT BMT, n ¼ 5; Arg1 KO BMT, n ¼ 5). (C) Flow cytometric analysis of splenocytes
showing that the amount of CD11bþ, CD11bþ/Ly6Chi, CD11bþ/Ly6Clowþmed monocytes and CD11bþ/Ly6Gþ neutrophils was signiﬁcantly decreased or trended to a decrease in spleens
of Arg1 KO recipients (*p < 0.05; WT BMT, n ¼ 5; Arg1 KO BMT, n ¼ 5). (D and E) A trend to a decrease in the amount of CD19þ and CD8þ splenocytes. The fraction of CD4þ and
CD4þCD25þ cells in the spleen was increased (*p < 0.05; $p < 0.05, respectively; WT BMT, n ¼ 5; Arg1 KO BMT, n ¼ 5), though the total amount of CD4þ and CD4þCD25þ cells in the
spleen was unchanged (p > 0.05; WT BMT, n ¼ 5; Arg1 KO BMT, n ¼ 5). (F) Representative ﬂow cytometry plots. Results are expressed as mean ± SEM, signiﬁcance was assessed by
Student t-test. *p < 0.05; $p < 0.05.
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lenge. As shown in Fig. 7, deletion of Arg1 in the bone marrow of
Ldlr KOmice led to increased total oxLDL-speciﬁc Ig levels (1.2-fold,
p < 0.05 compared to the WT BM Ldlr KO recipients after 10 weeks
WTD challenge), which was not driven by IgM.
4. Discussion
In the current study for the ﬁrst time the effects of Arg1 deletion
in bone marrow-derived cells on macrophage foam cell formation
and atherosclerosis susceptibility was determined. We show that
Arg1 expression is increased in elicited peritoneal macrophages
upon oxLDL-induced lipid loading and during the development of
early murine atherosclerotic lesions in the carotid-artery. Inagreement, Gallardo-Soler, Alejandro, et al., previously demon-
strated that Arg1 expression is highly induced in bone marrow-
derived macrophage foam cells upon oxLDL or acLDL stimulation
[30]. Inhibition of Ppar-g/d suppresses the lipid-induced increase in
macrophage Arg1 expression [30], indicating that Arg1 expression
is increased during macrophage foam cell formation probably due
to Ppar-g/d activation. Combined, these results indicate that Arg1
might participate in macrophage foam cell formation, thereby
inﬂuencing atherosclerosis development. However, so far there had
been no reports on the effects of Arg1 function on macrophage
foam cell formation. Interestingly, Arg1 KO BMDMs showed
increased foam cell formation both under control conditions and
after acLDL-induced lipid-loading compared to the WT BMDMs.
Genes involved in foam cell formation were investigated to gain
Fig. 7. Increased oxLDL-speciﬁc antibody levels in Ldlr KO mice transplanted with Arg1
KO BM after 10 weeks of WTD feeding. Total oxLDL-speciﬁc antibody and isotype IgM
levels were assessed using ELISA. Results are expressed as mean ± SEM, signiﬁcance
was determined by Student t-test. *p < 0.05 as compared between Ldlr KO recipient
with WT BM and recipients with Arg1 KO BM in the level of total oxLDL-Speciﬁc
antibody (Ig).
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mation in absence of Arg1. No difference was found in the
expression of Abca1, the primary cholesterol export transporter,
between WT and Arg1 KO macrophages. In response to acLDL
loading, Arg1 deﬁcient macrophages however did display an
impaired suppression of Srebp1 and Sr-b1 compared to WT mac-
rophages. Srebp1 is an important regulator of cellular lipid
biosynthesis [33], while Sr-b1 facilitates the uptake of native and
modiﬁed lipoproteins [34]. Enhanced foam cell formation of mac-
rophages lacking Arg1 might thus be explained by defective sup-
pression of cellular lipid biosynthesis and modiﬁed LDL uptake.
Moreover, upon lipid loading, macrophages lacking Arg1 seem
more likely to skew towards the M2 phenotype, as evidenced by
the signiﬁcantly downregulated M1 marker Inos and strongly
upregulated M2marker Fizz-1 expression in Arg1 KOmacrophages.
M2 macrophages exhibit increased cholesterol loading by oxLDL
compared to M1 macrophages, providing one possible mechanism
for the increased foam cell formation in our model [35,36].
Collectively, these ﬁndings suggest a link between Arg1 expression
andmacrophage foam cell formation. As Arg1 and Inos compete for
the common substrate L-arginine, macrophage Arg1 deﬁciency
indirectly leads to enhanced synthesis of NO upon lipid loading. The
observed downregulation of Inos in the Arg1 deﬁcient macro-
phages could thus be due to negative feedback by NO [10,37e41].
Notably, in agreement with our ﬁndings, excess NO has recently
been shown to induce oxLDL-induced macrophage foam cell for-
mation by inhibition of the LXR-Abca1-cholesterol efﬂux axis [42].
Next we investigated whether the observed increased foam cell
formation in vitro also translated into increased macrophage foam
cell formation in vivo and augmented atherosclerosis susceptibility.
Hereto, bone marrow from Arg1ﬂox/ﬂox;Tie2Cre mice was trans-
planted into Ldlr KO mice, a commonly used model to study
atherosclerosis. We decided to use Arg1ﬂox/ﬂox;Tie2Cre mice as do-
nors as the Tie2-cre deleter has previously been shown to lead to a
complete ablation of Arg1 activity inmacrophages, while in Arg1ﬂox/
ﬂox;LysMCre only ~80% reduction in macrophage Arg1 activity was
achieved [20]. In line with the observed increase in lipid accumu-
lation in Arg1 KO macrophages in vitro, foam cell formation in the
peritoneal cavity of Ldlr KO mice transplanted with Arg1 KO bone
marrow was increased after 10 weeks WTD feeding.
Foam cell formation in the peritoneal cavity is a marker for
atherosclerotic plaque development [43,44]. However, no differ-
ences in plaque size or plaque macrophage content were detected
between the Ldlr KO mice transplanted with Arg1 KO or WT bone
marrow. Increased expression of Arg1 in balloon-injured rabbitsresults in augmented plaque stability as a consequence of enhanced
VSMC proliferation [8]. Moreover, Arg1ﬂox/ﬂox;Tie2Cre (Arg1 KO)
mice exhibit impaired cutaneous wound healing, to some extent
due to impaired collagen deposition [43]. The reduced collagen
content in wounds of Arg1ﬂox/ﬂox;Tie2Cre (Arg1 KO) mice was
attributed to increased collagen degradation by neutrophils and
macrophages lacking Arg1 [45]. In atherosclerosis, collagen depo-
sition provides stability to the atherosclerotic plaque. However, no
signiﬁcant effect on the collagen-content of atherosclerotic plaques
of Ldlr KO mice transplanted with Arg1 KO bone marrow was
found. In the aortic root lesions, smooth muscle cells, the main
producers of collagen deposited in atherosclerotic lesions [46],
were not affected by deletion of Arg1 in bone marrow-derived cells
[47]. Conclusively, deletion of Arg1 in bone marrow-derived cells
does not affect atherosclerosis susceptibility despite a clear in-
crease in macrophage foam cell formation, indicating other
compensatory mechanisms.
Tie2 is expressed in all hematopoietic lineage cells [20].
Hence, in our bone marrow transplantation model using the
Arg1ﬂox/ﬂox;Tie2Cre mice as donors Arg1 is not only deleted in
macrophages, but in all hematopoietic cells [48]. For long it has
been thought that Arg1 is only expressed in the myeloid lineage
and not in the lymphoid lineages [49]. Indeed Arg1 is expressed
primarily in anti-inﬂammatory alternatively activated macro-
phages, however it can also be detected in neutrophils [50,51], and
innate lymphoid cells II (ILC2) [52].
To investigate whether bone marrow Arg1 deﬁciency had any
atheroprotective effects to counteract the observed increase in
foam cell formation, the leukocytes in blood and spleen, the major
hematopoietic organ and an important reservoir for monocytes,
were analysed in the BM transplanted mice. In agreement with
previous studies by Niese et al. [32], deletion of Arg1 in bone
marrow-derived cells did not affect circulating leukocytes on reg-
ular chow diet. Hypercholesterolemia is commonly known to
induce leukocytosis in animal models [53,54] and humans [55,56].
Upon challenge with a high fat/high cholesterol WTD, Ldlr KO mice
transplanted with Arg1 KO bone marrow failed to increase leuko-
cyte counts in the circulation. The inﬂammatory and pro-
atherogenic CD11bþ/Ly6Chi subset of monocytes gives rise to clas-
sically activated M1 macrophages in the atherosclerotic plaque
[57,58]. However, no difference was found in the numbers of
CD11bþ/Ly6Chi monocytes in blood, nor in the amount of circu-
lating neutrophils between the 2 groups of bone marrow recipients
after 10 weeks WTD challenge. Hypercholesterolemia-induced
monocytosis and neutrophilia was thus not affected in the blood
by deletion of Arg1 in bone marrow. In addition to myeloid cells
mobilization from bone marrow, high fat diet-induced inﬂamma-
tory conditions like atherosclerosis could also induce hematopoi-
etic stem and progenitor cells (HSPCs) settlement in the spleen and
leading to local production of monocytes and neutrophils [59,60].
Spleen-derived monocytes and neutrophils eventually inﬁltrate
into the growing atherosclerotic lesion, giving rise to foam cell
formation and pro-inﬂammatory cytokine production [60].
Notably, 30% of the total number of aortic monocytes were spleen-
derived Ly-6Chi monocytes, which are also reported to contribute to
foam cell formation in the lesions [60]. Arg1 depletion in bone
marrow leads to a signiﬁcant reduction of the CD11bþ cells,
CD11bþ/ly6Clowþmed monocytes and neutrophils in the spleen of
Ldlr KO mice and a tendency towards a decrease in pro-
inﬂammatory CD11bþ/Ly6Chi monocytes. This might provide an
atheroprotective mechanism counteracting the increased foam cell
in Ldlr KO mice transplanted with Arg1 KO BM.
As L-arginine is required for CD4þ T-cell function and matura-
tion, Arg1-mediated depletion of L-arginine by leukocytes results in
decreased T cell proliferation [17,61]. T cell counts and activation
B. Ren et al. / Atherosclerosis 256 (2017) 35e46 45status were therefore also investigated. However, there was no
difference in the amount of CD4þ cells and CD4þ/CD25þ in blood
and spleen, although a modest fractional increase in both subtypes
was found in the spleen. This indicates that leukocyte Arg1 is not a
strong regulating factor of T-cell proliferation in the spleen.
Notably, strikingly lower amounts of CD19þ B cells were found in
both the circulation and the spleen of Arg1 KO transplanted Ldlr KO
mice as compared toWT transplanted animals after 10 weeksWTD
challenge, explaining the decrease in total blood leukocyte counts.
L-arginine is an essential amino acid for B cell maturation in the
bone marrow and arginase-mediated L-arginine depletion leads to
reduced B cell emigration from the bonemarrow and reduced B cell
numbers in the spleen and lymph nodes [62]. If anything, leukocyte
Arg1 deletion is thus anticipated to enhance B cell emigration from
bone marrow, which clearly cannot explain the reduced B cell
numbers in blood. B cells, as the antibodies producing cell of the
immune system, play an important role in atherosclerosis. Anti-
oxLDL antibodies, especially IgM anti-oxLDL, are inversely related
to atherosclerotic plaque size in experimental studies [63]. There-
fore, oxLDL antibody levels were determined in plasma obtained
from recipient mice after 10 weeks WTD feeding. To our surprise,
despite the reduced numbers of B cells in the Ldlr KO recipients
transplanted with Arg1 KO BM, total oxLDL-speciﬁc antibody levels
were increased. OxLDL-speciﬁc IgM that is suggested to be athe-
roprotective [63], however, was not changed. Although in clinical
cardiovascular disease diverging results have been described on the
association between oxLDL-speciﬁc antibodies and atherosclerosis,
animal studies consistently suggest an atheroprotective role for
oxLDL antibodies [64]. Whatever the mechanism behind the
reduction in B cells and increased circulating levels of oxLDL-
speciﬁc antibodies, it might counteract the pro-atherogenic ef-
fects of enhanced foam cell formation in absence of Arg1.
We conclude that despite leading to an increase in foam cell
formation and a decrease in circulating B cells, Arg1 deﬁciency in
bone marrow-derived cells does not signiﬁcantly affect athero-
sclerotic plaque development.
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